Cell Therapeutics Audit Opinion 'Disclaimer'... Trading Suspended for Delisting Procedure
[Asia Economy Reporter Ji Yeon-jin] The Korea Exchange Market Division announced on the 30th that Selma Therapeutics falls under the "delisting criteria" as the auditor's opinion in the audit report for the 2020 fiscal year was "disclaimer of opinion."
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- After Topping 8,000 Instead of Hitting 10,000... KOSPI Plunges—When Will It Rebound?
- "They Said It's Impossible to Get—Already Selling for Triple the Price: Crowds Worldwide Line Up for $600 Luxury Watch"
- SK hynix Tops “Best Large Companies to Work For” Ranking Based on Employee Review Data
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
The company's stock will undergo the delisting procedure, and trading suspension will continue.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
